文献速递湿疹皮炎与荨麻疹

患者与照护者报告结局区分0.03%他克莫司与克立硼罗在儿童特应性皮炎中的效果

Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-02-15

该开放标签随机研究纳入47对儿童-照护者配对,比较克立硼罗与他克莫司0.03%治疗轻中度特应性皮炎12周的患者报告结局。两组疾病严重程度均改善,但仅他克莫司组在儿童和照护者多数报告结局上较基线显著改善(睡眠除外,均p<0.05)。提示患者报告结局可区分两种局部治疗对儿童及照护者负担的影响。

要点

  • 他克莫司0.03%较克立硼罗改善更多儿童与照护者报告结局(睡眠除外)。
  • 两组Eczema Area and Severity Index均从基线至12周下降(克立硼罗-2.4 vs 他克莫司-1.9)。
  • 12周局部治疗获益优于6周,未来试验应纳入患者报告结局。

核心结论

  • 12周局部治疗中,他克莫司0.03%较克立硼罗改善更多患者和照护者报告结局,但睡眠未改善。

研究设计与样本

  • 开放标签随机研究,47对儿童-照护者配对随机接受克立硼罗或他克莫司0.03%治疗12周,36对完成研究。

主要发现

  • 两组Eczema Area and Severity Index从基线至12周均下降(克立硼罗-2.4 vs 他克莫司-1.9)。
  • 组内分析显示,他克莫司组除睡眠外所有儿童和照护者报告结局较基线改善(均p<0.05),克立硼罗组未见。
  • 儿童基线为轻度特应性皮炎,平均年龄8.0±3.9岁,种族多样(39%白人;36%黑人),53%为男性。
  • 照护者多为女性(78%),平均年龄37±7.6岁。

临床怎么用

  • 对轻中度特应性皮炎儿童,选择局部治疗时可参考患者报告结局,他克莫司0.03%可能更有利于改善儿童及照护者报告的多项负担。

局限性

  • 开放标签设计,样本量较小(47对随机,36对完成),基线疾病严重程度为轻度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic skin disease that affects 20% of children worldwide and is associated with low patient-reported quality of life (QoL). Crisaborole (CRIS) and tacrolimus 0.03% (TAC) are Food and Drug Administration (FDA)-approved topical treatments for mild to moderate AD with similar clinical efficacy. Utilization of patient-reported outcomes (PROs) may provide meaningful data on the impact of AD treatments on patients and caregivers. This study used PROs to monitor the impact of crisaborole (CRIS) and tacrolimus 0.03% (TAC) on children with mild/moderate atopic dermatitis (AD) and caregiver burden. METHODS: This open-label study randomized 47 child-caregiver dyads to CRIS or TAC for 12 weeks. Disease severity, child quality of life (QoL), itch, pain interference, anxiety, depression, sleep, caregiver burden and caregiver QoL were assessed at baseline, 6 and 12 weeks. RESULTS: A total of 36 dyads completed the study. Children (mean age = 8.0 ± 3.9 years) had mild baseline AD and were diverse by race (39% white; 36% Black) and gender (53% males). Caregivers were mostly female (78%; mean age = 37 ± 7.6 years). Both arms improved disease severity (Eczema Area and Severity Index) from baseline to 12 weeks (CRIS = -2.4 vs. TAC = -1.9). Within-arm analyses comparing baseline to 12 weeks revealed TAC, but not CRIS, improved all child and caregiver PROs except sleep (all p < 0.05). CONCLUSIONS: Our results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ryan Wolf J, Chen A, Wieser J, et al. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2024. PMID: 38357778. doi:10.1111/jdv.19807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。